Solid Biosciences to Present at the Jefferies London Healthcare Conference

Core Viewpoint - Solid Biosciences Inc. is actively engaging in the life sciences sector, focusing on developing precision genetic medicines for neuromuscular and cardiac diseases, with a presentation scheduled at the Jefferies London Healthcare Conference [1]. Company Overview - Solid Biosciences is dedicated to advancing a portfolio of gene therapy candidates, including SGT-003 for Duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and AVB-401 for BAG3-mediated dilated cardiomyopathy, among others [3]. - The company aims to improve the daily lives of patients affected by rare neuromuscular and cardiac diseases, emphasizing a patient-focused approach and collaboration among experts in various fields [3]. Event Details - The presentation at the Jefferies London Healthcare Conference will take place on November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET) [1]. - A live webcast of the presentation will be available on the company's website, with a replay archived for 30 days [2].